

【書 籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
中野貴司	インフルエンザワクチンと COVID-19 ワクチンの同時接種 について	菅谷憲夫	インフルエンザ / 新型コロナ ウイルス感染症 診療ガイ ド 2022-23	日本医事新報社	東京	2022	274-6

【雑 誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Oba K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Nagura Y, Yanai H, Ueda A, Numata A, Kato H, Oka H, Nishida Y, Ooki T, Nidaira Y, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M.	Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies.	Euro Surveill.	28(4)	2300034	2023
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Aina A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T.	Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.	iScience.	26(2)	105969	2023
Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N.	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.	J Virol.	97(1)	e0136622.	2023
Sasaki M, Tabata K, Kishimoto M, Itakura Y, Kobayashi H, Ariizumi T, Uemura K, Toba S, Kusakabe S, Maruyama Y, Iida S, Nakajima N, Suzuki T, Yoshida S, Nobori H, Sanaki T, Kato T, Shishido T, Hall WW, Orba Y, Sato A, Sawa H.	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.	Sci Transl Med.	15(679)	eabq4064.	2023
Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, Ishizaka Y.	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.	Antiviral Res.	201	105297	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takahashi K, Ishikane M, Ujiiie M, Iwamoto N, Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, Kanno T, Saito S, Miyamoto S, Ainai A, Tobiume M, Arashiro T, Fujimoto T, Saito T, Yamato M, Suzuki T, Ohmagari N.	Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.	Emerg Infect Dis.	28(5)	998-1001	2022
Takagi A, Ohfuji S, Nakano T, Kumihashi H, Kano M, Tanaka T.	Incidence of mumps deafness in Japan, 2005-2017: analysis of Japanese insurance claims database.	J Epidemiol.	32(1)	21-6	2022
Nakashima K, Ishida M, Matsui H, Yoshida C, Nagai T, Shiraga M, Nakaoka H, Otsuka Y, Nakagama Y, Kaku N, Nitahara Y, Kido Y, and Hirota Y	Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.	Hum Vaccin Immunother.	18(6)	2140549	2022
Aoshima M, Ohfuji S.	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic.	Hum Vaccin Immunother.	18(7)	2147353	2022
Ohira S, Nakano T, et al.	Changes in serum antibody titers after vaccination for COVID-19 and evaluation of post-vaccination health conditions	Kawasaki Medical Journal	48	73-85	2022
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T.	Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.	Med (N Y).	3(4)	249-61	2022
Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, Wagatsuma A, Numata N, Sasaki K, Kuzuoka T, Yato Y, Takahashi Y, Maeda K, Suzuki T, Mizukami T, Hamaguchi I.	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.	Med (N Y).	3(6)	406-21	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M.	Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways.	Nat Commun.	13(1)	6100	2022
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y.	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.	Nature.	607 (7917)	119-27	2022
Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y.	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents.	Nature.	612 (7940)	540-5	2022
Takei S, Ai T, Yamamoto T, Igawa G, Kanno T, Tobiume M, Hiki M, Saito K, Khasawneh A, Wakita M, Misawa S, Miida T, Okuzawa A, Suzuki T, Takahashi K, Naito T, Tabe Y.	Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment.	PLoS One.	17(9)	e0274181	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, Tonouchi K, Terahara K, Sun L, Takano T, Nishiyama A, Shinkai M, Oba K, Nakamura-Uchiyama F, Shimizu H, Suzuki T, Matsumura T, Isogawa M, Takahashi Y.	SARS-CoV-2 Omicron- neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine.	Sci Immunol.	7(70)	eabn8590	2022
Okada K, Horikoshi Y, Nishimura N, Ishii S, Nogami H, Motomura C, Miyairi I, Tsumura N, Mori T, Ito K, Honma S, Nagai K, Tanaka H, Hayakawa T, Abe C, Ouchi K	Clinical evaluation of a new rapid immunochromatographic test for detection of Bordetella pertussis antigen	Sci Rep.	12(1)	8069	2022
Takahashi M, Ai T, Sinozuka K, Baba Y, Igawa G, Nojiri S, Yamamoto T, Yuri M, Takei S, Saito K, Horiuchi Y, Kanno T, Tobiume M, Khasawneh A, Paran FJ, Hiki M, Wakita M, Miida T, Suzuki T, Okuzawa A, Takahashi K, Naito T, Tabe Y.	Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies.	Sci Rep.	12(1)	14909	2022
Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Komiya E, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Kakeya H, Hirota Y.	Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.	Vaccine.	40(38)	5631-40	2022
Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Pneumonia in Elderly People Study Group.	Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.	Vaccine.	40(46)	6589-98	2022
Ohfuji S, Tanaka T, Nakano T, Kase T, Kondo K, Fukushima W, Hirota Y.	Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.	Vaccine.	40(7)	988-93	2022
Tokiya M, Hara M, Matsumoto A, Ashenagar MS, Nakano T, Hirota Y	Association of Vaccine Confidence and Hesitancy in Three Phases of COVID-19 Vaccine Approval and Introduction in Japan	Vaccines (Basel).	10(3)	423	2022
Ashenagar MS, Matsumoto A, Sakai H, Tokiya M, Hara M, Hirota Y	Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine	Vaccine(Basel).	10(4)	487	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y	Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case-Control Study	Vaccines (Basel).	10(5)	779	2022
Matsumoto A, Hara M, Ashenagar MS, Tokiya M, Sawada T, Iwasaka C, Furukawa T, Kitagawa K, Miyake Y, Hirota Y	Variant Allele of ALDH2, rs671, Associates with Attenuated Post-Vaccination Response in Anti-SARS-CoV-2 Spike Protein IgG: A Prospective Study in the Japanese General Population	Vaccines (Basel).	10(7)	1035	2022
Tokiya M, Hara M, Matsumoto A, Ashenagar MS, Nakano T, Hirota Y	Acceptance of Booster COVID-19 Vaccine and Its Association with Components of Vaccination Readiness in the General Population: A Cross-Sectional Survey for Starting Booster Dose in Japan	Vaccines (Basel).	10(7)	1102	2022
Hoshi SL, Okubo R, Tabuchi K, Seposo X, Shono A, Kondo M.	Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children	Vaccine.	40(37)	5513-22	2022
Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Natsuko Kaku, Matsumoto K, Suita A, Komiya E, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Takeya H, Hirota Y	Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan	Vaccine.	40(38)	5631-40	2022
Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M.	Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly	Vaccine.	40(49)	7057-64	2022
Tsurane K, Umehara N, Nakayama T, Okada K, Inoue M, Ogawa K, Sago H, Miyasaka N, Yamaguchi K	Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society	Vaccine.	40(49)	7122-9	2022
中野貴司	小児におけるワクチンの効果 (【特集】with コロナの小児医療の変化)	小児外科	第54巻、第6号	556-9	2022
中野貴司	新型コロナワクチンの成果と課題	皮膚病診療	第45巻、第1号	14-9	2023
中野貴司	COVID-19 ワクチンの現状と今後	臨床検査	第66巻、第8号	932-8	2022
岡田賢司	4種混合ワクチン	臨床と研究	99(4)	423-8	2022